Atherosclerosis Biomarkers Pharmacology 
DAIC
JANUARY 23, 2024
1,6 Until recently atherosclerosis has been thought of as the result of passive lipid accumulation in the vessel wall. However, the development of atherosclerosis is now known to be much more complex, with a key role for immune cells and inflammation in conjunction with hyperlipidemia and elevated LDL levels.7
Frontiers in Cardiovascular Medicine
MARCH 4, 2024
The complex development of atherosclerosis manifests as intimal plaque which occurs in the presence or absence of traditional risk factors. Atherosclerotic coronary artery disease (CAD) is the causal pathological process driving most major adverse cardiovascular events (MACE) worldwide.
Cardiometabolic Health Congress
OCTOBER 25, 2024
Keynote speaker and atherosclerosis expert Peter Libby, MD , captivated the audience with an update on his research into inflammation and atherosclerosis. He discussed therapeutic options not only for treating atherosclerosis but also for preventing cardiovascular disease. Experts like Louis J.
Journal of Cardiovascular Pharmacology
SEPTEMBER 4, 2023
Dysregulation of the innate and adaptive immune system is accelerated by CKD and results in increased systemic inflammation, a heightened local vascular inflammatory response leading to accelerated atherosclerosis, and dysfunction of the cardiac and renal endothelium and microcirculation.
Frontiers in Cardiovascular Medicine
FEBRUARY 20, 2025
We also examined the interaction between LVFP and the key targets using molecular docking techniques.ResultsLVFP significantly inhibited fibrosis biomarker such as hydroxyproline (HYP) and decreased myocardial fibrosis level as shown by heart weight to tibia length (HW/TL) measurement when compared to ISO-treated mice.
Expert insights. Personalized for you.
111 
Let's personalize your content